Annual Results Appendix 4E

“Since the launch of SCENESSE® in 2016, we have pursued clear and ambitious objectives for CLINUVEL, with a strong financial foundation and consistent performance being central. It is undeniable that – with seven years of growing revenues and profitability, continued R&D investment, and a formidable balance sheet to navigate uncertainty – we are meeting our long-term objectives and setting a standard for the future of the Group.

In parallel, strong cash inflows have enabled the Board to declare a sixth consecutive annual dividend for shareholders, recognising their long-term support. We will continue the strategy to translate our technology to the benefit of patients and the general population at high risk of DNA damage.”